The Valley Desk

NCT07573215 · Expanded access

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Overall registry status Approved for marketing

Conditions Metastatic Pancreas Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov